Medivation's most advanced compound is Dimebon, which enhances mitochondria function and is partnered with Pfizer (NYSE: PFE). It's believed that mitochondrial dysfunction leads to neuron death in neurodegenerative diseases like Alzheimer's and Huntington disease.

The first pivotal trial for Dimebon in Alzheimer's disease seems to have gone well, with Dimebon performing better than Aricept from Pfizer and Eisai, Razadyne from Johnson & Johnson (NYSE: JNJ), and Exelon from Novartis (NYSE: NVS) in at least one measurement. The caveat is that this wasn't a head-to-head trial, and comparing measurements across trials can be chancy because the trials may have enrolled patients with different characteristics.

Dimebon's next test will come from its phase 3 trial called Connection. The data is expected in the first half of the year, and Pfizer and Medivation could be filing for approval by year's end.
The companies are also testing Dimebon in a phase 3 trial in Huntington disease. PRESUMABLY, THEY WOULD MOVE INTO OTHER NEURODEGENERATIVE DISEASES LIKE PARKINSON'S AND ALS (amyotrophic lateral sclerosis) if Dimebon works in its current trials.

http://www.fool.com/investing/high-g...greatness.aspx